Table 1: Summary of literature found describing the relationship between ceftaroline use and neutropenia.

Authors

Year

Study Design

Population

Exposure

Neutropenia Development n (%)

Time to Neutropenia

Time to Normal ANC

Turner, et al.

2017

Retrospective multi-center cohort study

Adult patients admitted to a 6-hospital health system in Portland, Oregon from 2011-2017 (n = 753)

Ceftaroline therapy for ≥ 14 days

36 (4.8%)

Mean 20 days (25th-75th percentile, 15-29)

Mean 3 days (range 2-23)b

Jain, et al.

2014

Retrospective multi-center chart review

Adult patients at University of Washington and Harborview Medical Centers  from 2011 to 2012 (n = 12)

600 mg IV ceftaroline every 8 or 12 hours

4 (33%)

Mean 31 days.

(Range 22-40)c

-

Furtek, et al.

2016

Retrospective multi-center chart review

Adult patients from Massachusetts General Hospital and Brigham and Women’s Hospital from 2010 to 2015 (n = 67)

Ceftaroline therapy for ≥ 7 days

7 (10%)

Mean 29 days (range 13-64)

Mean 9 days (range 3-14)

Zasowski, et al.

2017

Retrospective multi-center chart review

Adult patients from 2011-2015 at Detroit Medical Center, UF Health-Shands Hospital, or Henry Ford Hospital (n = 211)

Ceftaroline treatment

3 (1.4%)

Mean 16 days (range 13-20)

-

Lavie, et al.

2016

Retrospective single-center chart review

Adult patients admitted to an 800-bed academic medical center from 2012 to 2014 (n = 39)

Ceftaroline therapy for ≥ 7 days

7 (18%)

Median first neutropenic day was day 17

Within 1 month

Jansen, et al.

2017

Retrospective single-center chart-review

Patients at VA St. Louis Health Care System (n = 75)

At least one dose of ceftaroline from 2010-2017

3 (4%)

Mean 40 days (range 37-42)

-

Rimawi, et al.

2013

Case Study

90-year-old female (n = 1)

600 mg IV ceftaroline every 12 hours

1 (100%)

25 days

1 week

Yam, et  al.

2014

Case Study

67-year-old Caucasian man (n = 1)

600 mg IV ceftaroline every 8 hours

1 (100%)

3 weeks

9 days

 

a)       In patients developing neutropenia

b)       In those with consecutive days of neutropenia (19 out of 36 patients)

c)       Time to discontinuation due to development of neutropenia